Results

1–10 of 45 results for Dry AMD

Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2024
Delayed Near Infrared Analysis Identifies Novel Features of Nonexudative Dry Age-Related Macular Degeneration in a Natural History Study: Baseline Findings
Shelley Boyd, MD, FRCS(C)
Annual Meeting Talks
2024
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Debate: How Should We Treat Geographic Atrophy
Ajay E Kuriyan, MD, MS
Updates from the Field
2024
Machine and Deep Learning (AI) Algorithms for GA Identification and Prediction of Progression to GA from Intermediate AMD: The Future of Dry AMD Management
Eleonora Lad, MD, PhD
Updates from the Field
2023
Dual Anti-platelet Therapy Decelerates the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Yodpong Chantarasorn, MD
On Demand Cases, Courses, and Papers
2021
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021